Critical care nephrology is an emerging sub-specialty with rapid technological advancement and a growing body of dedicated literature in blood purification techniques. Their applications have been extended to improve morbidity and survival in multiple organ dysfunctions. Novel techniques have also allowed us to push the frontiers in transplant medicine, giving high-immunological risk patients a chance at a kidney transplant where this was previously precluded by hyperacute antibody-mediated rejection. We aim to review the myriad extracorporeal blood purification techniques now available for treating various critical illnesses in our clinical practice. Some of these techniques will still require further clinical research to determine the optimal timing and dose in order to achieve significant improvement in clinical outcomes.
IntroduCtIon
Blood purification in critical illness is probably most familiar to intensivists and nephrologists when it is utilised in the form of renal replacement therapy in acute kidney injury (AKI). Use of continuous arteriovenous haemofiltration (CAVH) for the treatment of patients with haemodynamic instability was reported in 1977 1 . However, arterial cannulation in CAVH was associated with significant morbidity and efficacy was variable as it was dependent on patients' blood pressure. Technology has since evolved to achieve better performance and safety in dialysis. These new developments have also extended the use of blood purification techniques beyond renal replacement therapy to the treatment of multiple organ dysfunctions. We aim to review the use of extracorporeal blood purification in various critical illnesses.
MECHAnIsMs oF EXtrACorPorEAL BLood PurIFICAtIon Diffusion
Solute transport occurs through a semi-permeable membrane down its concentration gradient.
Clearance is dependent on solute molecular weight, concentration gradient across the membrane, membrane permeability and surface area, blood flow rate, dialysate flow rate and duration of dialysis.
Convection
Solute transport occurs through a semipermeable membrane as part of "solvent drag" when ultrafiltration is driven by a transmembrane pressure gradient. Solute clearance is determined by transmembrane pressure gradient, ultrafiltration coefficient K UF , membrane surface area and duration.
Adsorption
Blood or plasma is passed through sorbents which attract solutes through hydrophobic or ionic interactions so that solutes adhere ("adsorb") onto the sorbents. Activated charcoal is an example of a sorbent which adsorbs solutes onto its surface via van der Waal's forces. Solute clearance depends on the solute size, affinity to sorbent and ability to penetrate the porous membrane.
Review
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Proceedings of Singapore Healthcare  Volume 21  Number 2  2012 soLutE FACtors AFFECtInG EXtrACorPorEAL BLood PurIFICAtIon Molecular Weight Low molecular weight solutes (less than 500 Daltons) reach equilibrium rapidly in diffusive transport. Hence increment in blood or dialysate flow rates will significantly increase solute clearance, compared to large molecules whose clearance plateau or increase non-linearly with increment in blood or dialysate flow rates. These larger molecules are more effectively cleared by convection since this is independent of solute size.
Protein Binding and Volume of Distribution
Only free, unbound solutes in the plasma are available for removal by diffusion or convection. Highly protein-bound solutes or those with large volumes of distribution are generally not dialysable. However, some of these solutes may be cleared by other blood purification techniques such as haemoperfusion or albumin dialysis.
sYstEM FACtors AFFECtInG EXtrACorPorEAL BLood PurIFICAtIon Vascular Catheter
A central venous catheter is used to conduct blood between the patient and the extracorporeal circuit. The ideal vascular catheter should provide adequate blood flow rates to achieve the target solute clearance and with minimal complications such as infections and thrombosis. By Poiseulle's law, laminar flow within the lumen is determined by lumen length and diameter. Hence, blood flow should be optimised using a straight, short and wide catheter at an appropriate cannulation site. However, dual-lumen catheters are prone to recirculation which may compromise the net dialysis effect.
Membrane
The mass transfer area coefficient K OA is the in-vitro ability of a dialyser to remove a solute. Each dialyser has an estimated solute clearance expected for each combination of blood flow rate and dialysate flow rate.
The ultrafiltration coefficient K UF is the volume of plasma water filtered per unit transmembrane pressure. This is a measure of membrane permeability to water.
Anticoagulation
The extracorporeal circuit is prone to clotting when blood comes into contact with tubings, membranes or sorbents, resulting in blood loss and decreased delivery of dialysis dose 2 . Hence, most extracorporeal circuits will require anticoagulation.
Systemic anticoagulation with unfractionated heparin requires continuous infusion into the circuit inflow limb with regular monitoring of activated partial thromboplastin time (aPTT) to aim aPTT 1.5-2 times upper limit normal. Yet, use of systemic anticoagulation may be complicated by bleeding episodes in critically ill, coagulopathic patients and is contraindicated in patients with heparin-induced thrombocytopenia.
Regional citrate anticoagulation is an alternative which offers comparable filter patency with reduced bleeding risks. A multi-centre randomised study of 174 patients randomised to either regional citrate anticoagulation or systemic heparin in predilution continuous venovenous haemofiltration (CVVH) found increased filter patency (37.5 ± 23 h vs. 26.1 ± 19 h, P <0.001) 3 . Caution is advised in patients with liver failure and the biochemistry should be monitored for citrate toxicity. Figures 1 to 7 illustrate the simplified circuits for each type of blood purification technique: Figure 1 . Blood is drawn from a vein and returned to the same vein using a dual-lumen catheter in the veno-venous technique. Adequate blood flow is achieved and maintained using a prefilter peristaltic pump. A haemofilter with high K UF allows large volumes of ultrafiltrate to pass through, achieving solute clearance by convection. Replacement fluid can be administered into the circuit pre-or post-filter. Figure 2 . A dialysate solution is circulated in the filter counter-current to blood flow. Solute clearance is based on diffusion from the blood compartment into the dialysate fluid depending on the solute concentration gradient. Figure 3 . This is a "hybrid" therapy using both diffusion and convective mechanisms for solute transport. The "continuous" modalities have lower small molecule clearance per unit time compared to intermittent therapies; hence therapy time is prolonged over 24 hours.
tYPEs oF EXtrACorPorEAL BLood PurIFICAtIon tHErAPIEs usEd In CrItICALLY ILL PAtIEnts
Continuous Venovenous Haemofiltration (CVVHF)
Continuous Venovenous Haemodialysis (CVVHD)
Continuous Venovenous Haemodialfiltration (CVVHDF)
Replacement and dialysate fluid in the above continuous renal replacement therapy (CRRT) modalities (CVVH, CVVHD, CVVHDF) are generally commercially prepared solutions such as Prismasol B0® (Gambro, Lund, Sweden).
Standard Intermittent Haemodialysis (HD)
Blood flow rates range from 250-350 mL/min and dialysate flow rates are typically 400-600 mL/min. At such rapid flow rates, diffusive transport of small solutes across the haemodialyser membrane is highly efficient, enabling shorter therapy duration.
Sustained Low Efficiency Dialysis (SLED)
This modality is similar to intermittent HD but blood and dialysate flow rates are slower, resulting in less haemodynamic fluctuation.
Intermittent Haemodialfiltration (HDF)
This hybrid therapy utilises both diffusive and convective solute transport mechanisms to increase removal of middle molecules compared to standard intermittent HD or SLED. Typical blood flow rates range from 150-200 mL/min while dialysate flow rates and replacement flow rates are 200-400 mL/min and 1000-2000 mL/h, respectively. Each session may last four to eight hours.
High Volume Haemofiltration (HVHF)
Continuous HVHF is a variant of CVVH with larger therapy volumes of up to 50-70 mL/kg/h for 24 hours each day. Intermittent "pulse" HVHF is defined as brief, very-high-volume treatment at 100-120 mL/kg/h for four to eight hours 4 . Figure 4 . Whole blood is circulated through thin, porous membranes containing sorbents. Figure 5 . Plasma exchange involves separation of plasma from blood by centrifugation or plasma filtration using membranes with pore diameters of 0.20-0.30 μm. This volume is then replaced by saline, albumin or fresh frozen plasma.
Haemoperfusion or Haemoadsorption
Selective Plasmapheresis Techniques a. Plasma Exchange
However, plasma exchange is limited by risks of exposure to blood products and costs of large volumes of recombinant human albumin required.
b. Coupled Plasma Filtration Adsorption (CPFA) Figure 6 . Plasma filtration is coupled to sorbent technology in CPFA. Separated plasma is circulated through sorbent columns and then returned to blood within the extracorporeal circuit where it passes through a haemodialyser before returning to the patient.
CPFA allows regeneration of plasma, hence avoiding the complications of plasma volume replacement fluids which may occur in plasma exchange.
c. Coupled Plasma Filtration Immunoadsorption (CPFIA)
This technique is similar to CPFA except that the sorbent used are beads with immobilised antigens or specific monoclonal antibodies. An example is Protein A (a 42 kDalton protein derived from Staphyloccocus aureas) which adsorbs immunoglobulin.
rEnAL rEPLACEMEnt tHErAPY (rrt) In ACutE KIdnEY InjurY (AKI)
AKI in critically ill patients is associated with high mortality of up to 60% 5 . Since many of these patients will require RRT, optimisation of acute renal replacement therapy (ARRT) may impact patient outcomes.
Dialysis Modalities
Both intermittent (IRRT) and continuous (CRRT) dialysis modalities can be used in the treatment of AKI. A meta-analysis of nine randomised studies with a total of 1403 patients found no statistical evidence that initial modality affected mortality (OR 0.99, P = 0.93) or renal recovery (OR 0.76, P = 0.59), although CRRT was associated with fewer episodes of haemodynamic instability and better control of fluid balance 6 . This was confirmed in a multicentred, randomised study comparing intermittent Proceedings of Singapore Healthcare  Volume 21  Number 2  2012 daily dialysis versus post-dilution CVVH which found no difference in hospital mortality (62.5% vs. 58.1%, P = 0.43) or renal impairment as defined by estimated glomerular filtration rate (eGFR) at time of discharge (eGFR <15 mL/min/1.73 m 2 in 25.5% of IRRT group vs. 16.9% of CRRT group, P = 0.474) 7 .
Studies comparing modalities usually limit the study to patients whom both modalities are considered safe, hence results may not be generalisable to sicker patients with severe haemodynamic instability, brain injury or acute liver failure. For instance, the American Association for Study of Liver Disease advised that patients with acute liver failure requiring dialysis should receive continuous modes of RRT in view of improved stability in intracranial parameters compared to intermittent dialysis 8 .
Dialysis Intensity
Two large multi-centred randomised controlled studies in the United States and Australia have investigated the issue of optimal dialysis dosing in the critically ill patient with AKI. The Acute Renal Failure Trial Network study was the first large, multi-centred randomised clinical trial to assess the impact of RRT intensity in these patients 9 ; 1124 patients were randomised to either intensive therapy (SLED or intermittent haemodialysis 6 sessions per week or pre-dilution CVVHDF with Table 1 . Classification of AKI Severity in the RIFLE and AKIN Systems.
RIFLE Classes 11
AKIN Stages 12 Risk Increase in serum creatinine to more than or equal to 1.5 times of baseline OR Decrease in GFR more than 25% OR Urine output less than 0.5 ml/kg per hour for more than 6 hours
Stage 1
Increase in serum creatinine of more than or equal to 0.3 mg/dl (26.4 μmol/L) or increase to more than or equal to 1.5 to 2-fold from baseline OR Urine output less than 0.5 ml/kg per hour for more than 6 hours Injury Increase in serum creatinine to more than or equal to 2 times of baseline OR Decrease in GFR more than 50% OR Urine output less than 0.5 ml/kg per hour for more than 12 hours
Stage 2
Increase in serum creatinine to more than 2 to 3fold from baseline OR Urine output less than 0.5 ml/kg per hour for more than 12 hours
Failure
Increase in serum creatinine to more than or equal to 3 times of baseline OR Serum creatinine is greater than 4.0 mg/dL (350 μmol/L) with an acute increase of at least 0.5 mg/dL (44 μmol/L) OR Decrease in GFR > 75% OR Urine output less than 0.3 ml/kg per hour for 24 hours or anuria for 12 hours
Stage 3
Increase in serum creatinine to more than 3-fold from baseline OR Serum creatinine of more than or equal to 4.0 mg/dL (354 μmol/L) with an acute increase of at least 0.5 mg/dL ( 
Dialysis Initiation
The traditional indications for RRT initiation in the presence of severe metabolic acidosis, severe volume overload or uremic complications are now considered as inadequate in the current paradigm of "renal support" therapy. However, earlier studies evaluating timing of RRT initiation were retrospective or observational in nature and not comparable due to heterogeneous definitions for AKI.
The RIFLE classification 11 , proposed by the Acute Dialysis Quality Initiative, was based on change in serum creatinine, glomerular filtration rate (GFR) and urine output. The AKIN classification defined AKI as increased creatinine >0.3 mg/dL (26.4 µmol/L) from baseline or increased creatinine >50% from baseline OR oliguria <0.5 ml/kg/h >6 hours within 48 hours, in the absence of volume depletion and urinary tract obstruction 12 . The AKIN staging for AKI severity was modified from RIFLE classes ( Table 1 ) and has been shown to correlate with patient outcomes 13 and recently adopted by the Kidney Disease: Improving Global Outcomes (KDIGO) workgroup in their 2012 Clinical Practice Guidelines 14 . A recent prospective study in postsurgical patients using these standardised staging criteria indicates improved survival and renal recovery with earlier initiation of RRT 15 . The multiple complex considerations leading to a decision to initiate RRT in actual clinical practice underlies the difficulty in designing randomised controlled studies to investigate this aspect. Of interest, emerging novel biomarkers may facilitate early diagnosis and further enhance risk stratification so as to better guide the optimal timing of RRT initiation 16 .
BLood PurIFICAtIon In sEPsIs
Sepsis is the most common cause of admission to the intensive care unit 17 with mortality rates of up to 50% in septic shock 18 . There is growing interest in the use of blood purification techniques in the clearance of harmful cytokines involved in the systemic inflammatory response (SIRS) 19 . CVVH alone may be inadequate in removing significant numbers of tumour necrosis factor alpha (TNFalpha) or interleukins compared to endogenous clearance 20 ; but emerging therapies such as high cut-off haemofilter membranes, high-volume haemofiltration (HVHF), haemoperfusion and CPFA can augment removal of these larger molecules.
HVHF has been shown to improve cardiac output in animal studies 21 . Joannes-Boyau et al treated 24 septic shock patients with high volume CVVH (ultrafiltration rates ranged from 40 mL/kg/h to 60 mL/kg/h) for 96 hours 22 . All 24 patients achieved significant improvement in blood pressures and corresponding reduction in norepinephrine doses. There was also improvement in these patients' observed mortality compared to their predicted 28-day mortality. These findings were reiterated in other observational studies 23, 24 . However, largescale studies are lacking. Currently, Acute Dialysis Quality Initiative (ADQI) suggests that HVHF may be used in catecholamine-resistant septic shock by clinicians familiar with HVHF therapies 25 . Plasma exchange as an adjuvant therapy in severe sepsis and septic shock was evaluated in a single-centre study of patients with high APACHE III scores 28 . The plasmapheresis group received the first treatment within six hours of diagnosis and a second treatment within 24 hours if there was no clinical improvement. The intervention group had lower 28-day mortality (33.3% vs. 53.8%, P = 0.05) although this difference was diminished after multiple logistic regression. There are few publications describing CPFA use in septic patients but a pilot study demonstrated improved haemodynamics 29 .
A new generation of membranes such as oXiris™ (Gambro, Lund, Sweden) focusing on endotoxin adsorption has emerged and clinical outcome studies are eagerly anticipated.
BLood PurIFICAtIon In HEPAtIC FAILurE
Critically ill patients with acute liver failure (ALF) and those with underlying cirrhosis admitted to the ICU have high mortality 30, 31 . Toxins which are usually metabolised by the liver, including hydrophilic solutes such as ammonia and hydrophobic proteinbound solutes such as bilirubin, accumulate in liver failure and may lead to encephalopathy, AKI and systemic hypotension. Selective extracorporeal removal of these molecules aims to support liver detoxification and bridge patients with ALF or acute-on-chronic liver failure (AoCLF) to either recovery or orthotropic liver transplantation.
Single pass albumin dialysis is similar to a CVVHDF circuit. The patient's blood flows through a standard albumin-impermeable high-flux dialyser, countercurrent to an albumin-containing dialysate.
Protein-bound molecules that are small enough to pass through the membrane pores are removed by diffusion. The albumin dialysate is discarded after a single passage ("pass") through the dialyser.
Molecular Adsorbent Recirculating System (MARS®, Gambro, Lund, Sweden) utilises the concept of albumin dialysis. "Spent" albumin dialysate is regenerated in a secondary circuit consisting of charcoal and an anion exchanger resin in series to remove albumin-bound solutes by adsorption.
The "regenerated" albumin is then returned to the primary circuit as dialysate (Fig. 7) . MARS® therapy improved hepatic encephalopathy 32 and renal function 33 , but there is inadequate evidence for survival benefit compared with standard medical therapy. An early study showing lower 30-day mortality rates in MARS did not include vasopressin analogues or transjugular intrahepatic portosystemic shunt in standard treatment 34 . In a meta-analysis by Khuroo et al, MARS® treatment did not reduce mortality significantly compared with standard medical treatment (Relative Risk 0.56, P = 0.11) 35 . Similarly, the largest extracorporeal liver support study to date, the RELIEF trial, did not demonstrate a statistically significant beneficial effect of MARS® on 28-day survival for patients with AoCLF 36 .
There were concerns about bleeding risks secondary to thrombocytopenia and coagulopathy 37 , but local experience found anticoagulant-free MARS® therapy to remain safe and effective 38 .
Fractionated plasma separation and adsorption (FPSA) is coupled to haemodialysis in Prometheus® (Fresenius Medical Care, Bad Homburg, Germany). An albumin-permeable filter is used to separate albumin-rich plasma which then enters a secondary circuit and passed through a resin adsorption column and an anion exchanger. Albumin-bound toxins are retained in these adsorption columns. The "cleansed" plasma is returned to the primary circuit where a conventional dialyser is used to remove water-soluble toxins by diffusion before returning to the patient. Prometheus® is comparable with MARS® in blood clearances of toxins such as bilirubin, bile acids and creatinine 39 and has also been used to treat hepatic encephalopathy 40 and hepatorenal syndrome 41 . The HELIOS trial in 145 patients with AoCLF reported no statistical difference in 90-day survival between Prometheus and standard medical therapy (47% vs. 38%, P = 0.35), but a sub-group analysis found improved survival in patients with hepatorenal syndrome type I or MELD score >30 treated with Prometheus 41 .
A bioartificial liver is a more ideal liver "replacement" therapy as it incorporates liver cells capable of synthetic function, in addition to detoxification. However, such bio-hybrid systems are highly complex, inaccessible and not in routine clinical use.
BLood PurIFICAtIon In HuMorAL-MEdIAtEd dIsEAsE
Immunomodulation with extracorporeal blood Proceedings of Singapore Healthcare  Volume 21  Number 2  2012 purification techniques involves removing plasmaborne humoral disease mediators so as to suppress normal recognition and immune response and hence attenuate disease severity and progression. Such mediators include immunoglobulins and circulating immune complexes (CIC).
Evidence-based guidelines by the American Society for Apheresis 42 and the American Academy of Neurology 43 , advocate the use of plasma exchange as adjuvant therapy in diseases such as acute and chronic inflammatory demyelinating polyneuropathy, anti-glomerular basement membrane (anti-GBM) disease and thrombotic thrombocytopenic purpura-haemolytic uremic syndrome (TTP-HUS). Locally, TTP-HUS syndrome is a typical indication for plasma exchange therapy. A case series of 11 patients treated in the Singapore General Hospital from 1997 to 2002 reported response in eight patients and complete remission in six patients 44 .
CPFIA with Immusorba™ columns (Asahi Medical, Tokyo, Japan) and Prosorba® columns (Cypress Bioscence, San Diego, USA) have been reported to be effective in treating autoimmune neurological diseases such as Gullain-Barré syndrome 45 ; rheumatologic diseases such as systemic lupus erythematosus 46 and rheumatoid arthritis 47 ; and haematological diseases such as autoimmune thrombocytopenic purpura 48 . The results from current literature, comprising mainly small case series or uncontrolled comparative studies, are encouraging but large-scale randomised trials and cost-effectiveness studies are warranted prior to routine clinical use of these expensive adsorption columns.
The presence of donor-specific anti-HLA antibodies or ABO-incompatibility is associated with high graft loss rates from antibody-mediated rejection and thus a barrier to kidney transplantation for patients with end-stage kidney failure. Therapeutic apheresis with either plasma exchange 49 or CPFIA with Protein A adsorption columns 50 , as part of desensitisation protocols, can remove donorspecific antibodies to permit high-immunologic risk transplants, including ABO-incompatible transplants 49, 51 . Expanding the donor pool by such blood purification techniques may become increasingly relevant and important in our rapidly growing end-stage renal failure (ESRF) population because of limited deceased-donor organ availability 52 .
BLood PurIFICAtIon In toXICoLoGY
Extracorporeal blood purification may be used as adjuvant therapy to supplement drug elimination in intoxications where extracorporeal solute clearance exceeds that of endogenous solute clearance.
Previously, standard haemodialysis was limited to removal of low molecular weight, water-soluble drugs such as lithium and methanol. Intoxication with protein-bound drugs such as theophylline, phenobarbitone and carbamazepine generally required treatment with activated charcoal haemoperfusion 53, 54 . However, haemoperfusion is associated with adverse effects such as thrombocytopenia, leucopenia and hypocalcaemia. Haemoperfusion cartridges are also expensive and less familiar to most intensive care personnel compared to haemodialysis. Registry data from the United States Toxic Exposure Surveillance System between 1985 and 2005 showed that among the 19,351 patients treated with extracorporeal toxin removal, haemoperfusion use decreased while haemodialysis use increased 55 . The decreased utilisation of charcoal haemoperfusion has been attributed to improved haemodialysis efficacy in toxin removal, particularly with the use of high flux membranes 56 . Analysing carbamazepine concentration in serum and effluent fluid, Kielstein et al concluded that carbamazepine clearance by haemodialysis using high-flux dialyser for 3.5 hours was similar to clearance by a two-hour haemoperfusion session 57 . A 10-year prospective observational study of theophylline intoxication in 56 patients found that despite higher clearances achieved by haemoperfusion, there was no difference in the incidence of major theophylline toxicity in patients who received haemoperfusion versus those who received haemodialysis (18% vs. 33%, P = NS) 58 .
Despite the above, there are few randomised controlled trials evaluating clinical outcomes of extracorporeal blood purification in toxicology. in various clinical conditions. The efficacy of each technique should be viewed in context of the amount of solute cleared compared to endogenous production, as well as clinical outcomes such as mortality, morbidity and safety. However, research in blood purification is hampered by heterogeneous patient populations, difficulty conducting large randomised studies in critically ill subjects, and uncertainty whether surrogate measures of dialysis efficacy, for example, solute concentration, correlate with pathophysiological processes and clinical outcomes.
ConCLusIon
Regardless of the extracorporeal technique selected, it is essential to provide adequate physician and nursing training with regular competency assessment in the use of these different modalities.
Lastly, emphasis must be placed on the holistic care of the critically ill patient receiving extracorporeal blood purification. A multidisciplinary team should give consideration to alterations in pharmacokinetics of drugs commonly used in the ICU, as well as adequacy of nutritional support, as these may be altered by the underlying disease and exacerbated by the type and dose of extracorporeal technique used. 
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